title: In vitro pharmacodynamics of various antibiotics in combination against extensively drug-resistant Klebsiella pneumoniae.
abstract: Extensively drug-resistant (XDR) Klebsiella pneumoniae is an emerging pathogen in Singapore. With limited therapeutic options available, combination antibiotics may be the only viable option. In this study, we aimed to elucidate effective antibiotic combinations against XDR K. pneumoniae isolates. Six NDM-1-producing and two OXA-181-producing K. pneumoniae strains were exposed to 12 antibiotics alone and in combination via time-kill studies. A hollow-fiber infection model (HFIM) with pharmacokinetic validation was used to simulate clinically relevant tigecycline-plus-meropenem dosing regimens against 2 XDR K. pneumoniae isolates over 240 h. The emergence of resistance against tigecycline was quantified using drug-free and selective (tigecycline at 3× the MIC) media. The in vitro growth rates were determined and serial passages on drug-free and selective media were carried out on resistant isolates obtained at 240 h. Both the polymyxin B and tigecycline MICs ranged from 1 to 4 mg/liter. In single time-kill studies, all antibiotics alone demonstrated regrowth at 24 h, except for polymyxin B against 2 isolates. Tigecycline plus meropenem was found to be bactericidal in 50% of the isolates. For the isolates that produced OXA-181-like carbapenemases, none of the 55 tested antibiotic combinations was bactericidal. Against 2 isolates in the HFIM, tigecycline plus meropenem achieved a >90% reduction in bacterial burden for 96 h before regrowth was observed until 10(9) CFU/ml at 240 h. Phenotypically stable and resistant isolates, which were recovered from tigecycline-supplemented plates post-HFIM studies, had lower growth rates than those of their respective parent isolates, possibly implying a substantial biofitness deficit in this population. We found that tigecycline plus meropenem may be a potential antibiotic combination for XDR K. pneumoniae infections, but its efficacy was strain specific.
authors.affiliation: Department of Pharmacy, Singapore General Hospital, Singapore Department of Medicine, National University Hospital System, Singapore.
authors.forename: Tze-Peng
authors.initials: TP
authors.lastname: Lim
authors.affiliation: Department of Pharmacy, Singapore General Hospital, Singapore.
authors.forename: Yiying
authors.initials: Y
authors.lastname: Cai
authors.affiliation: Department of Pharmacy, National University of Singapore, Singapore.
authors.forename: Yanjun
authors.initials: Y
authors.lastname: Hong
authors.affiliation: Department of Pharmacy, National University of Singapore, Singapore.
authors.forename: Eric Chun Yong
authors.initials: EC
authors.lastname: Chan
authors.affiliation: Department of Pharmacy, Singapore General Hospital, Singapore.
authors.forename: Sasikala
authors.initials: S
authors.lastname: Suranthran
authors.affiliation: Department of Pharmacy, Singapore General Hospital, Singapore.
authors.forename: Jocelyn Qi-Min
authors.initials: JQ
authors.lastname: Teo
authors.affiliation: Department of Pharmacy, Singapore General Hospital, Singapore.
authors.forename: Winnie Huiling
authors.initials: WH
authors.lastname: Lee
authors.affiliation: Department of Laboratory Medicine, Changi General Hospital, Singapore.
authors.forename: Thean-Yen
authors.initials: TY
authors.lastname: Tan
authors.affiliation: Department of Medicine, National University Hospital System, Singapore.
authors.forename: Li-Yang
authors.initials: LY
authors.lastname: Hsu
authors.affiliation: Department of Pathology, Singapore General Hospital, Singapore.
authors.forename: Tse-Hsien
authors.initials: TH
authors.lastname: Koh
authors.affiliation: Department of Infectious Diseases, Singapore General Hospital, Singapore.
authors.forename: Thuan-Tong
authors.initials: TT
authors.lastname: Tan
authors.affiliation: Department of Pharmacy, Singapore General Hospital, Singapore Emerging Infectious Diseases, Duke-NUS Graduate Medical School, Singapore andrea.kwa.l.h@sgh.com.sg.
authors.forename: Andrea Lay-Hoon
authors.initials: AL
authors.lastname: Kwa
mesh_terms: D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics* / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial; D007711:Klebsiella pneumoniae / Q000187:drug effects*; D000077731:Meropenem; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D011112:Polymyxin B / Q000493:pharmacokinetics* / Q000494:pharmacology*; D013845:Thienamycins / Q000493:pharmacokinetics / Q000494:pharmacology; D000078304:Tigecycline
chemical_list: D000900:Anti-Bacterial Agents; D013845:Thienamycins; D000078304:Tigecycline; D000077731:Meropenem; D008911:Minocycline; D011112:Polymyxin B